Your browser is currently blocking notification.
Please follow this instruction to subscribe:
X
Notifications are already enabled.
X

1mg Records 223% Revenue Growth In FY18, But At A High Cost

1mg Records 223% Revenue Growth In FY18, But At A High Cost

1mg reported a total revenue of INR 39.8 Cr ($5.4 Mn) in FY18

Epharmacy contributed the maximum to the total revenue with INR 23.2 Cr ($3.1 Mn), a 268% jump from FY17

1mg also reported a net loss of INR 88 Cr ($11.9 Mn), a 50% increase from the last financial year

1mg Technologies, an epharma company, recently released its financials for FY 2017-18. According to the documents, sourced from Tofler, the company reported its revenues for the period ending March 31, 2018, as INR 39.8 Cr ($5.4 Mn), a 223% jump from the last financial year.

1mg was launched in April 2015 after Healthkart separated its generic drug search business, HealthkartPlus, and rebranded it as 1mg, to be operated under 1mg Technologies Pvt Ltd. The company operates under three business vertical heads: Pharmaceuticals (www.1mg.com), Labs (www.1mglabs.com), Doctors (www.1mgdoctors.com).

Of the total revenue, the epharmacy contributed INR 23.2 Cr ($3.1 Mn) while the diagnostics share was INR 8.8 Cr ($1.1 Mn) in FY18, an increase of 268% and 214% respectively from FY17. The company further reported a net loss of INR 88 Cr ($11.9 Mn) during the fiscal. This is about a 50% increase from the last financial year.

However, the increase in absolute expenses in the last fiscal was much more than the increase in revenues. The company’s total expenses for the fiscal were reported as INR 128 Cr ($17.4 Mn). The increase in expenses was significantly contributed by advertising expenses, which doubled from INR 22 Cr ($2.9 Mn) in the previous fiscal to INR 48 Cr ($6.5 Mn) this financial year.

The increased expenses also had an impact on the company’s growth rate for FY18. As Inc42 reported earlier as part of a June 2018 analysis in its What The Financials series, 1mg reported a growth rate of 263% on the basis of its total income, which has now dropped to 223% in FY18.

1mg’s major competitors are other epharma players such as Healthkart, PharmEasy, and NetMeds, among others. As noted by Inc42 in the FY17 analysis, 1mg has been growing at a fast pace, but with a significantly higher cost as compared to its peers. Startups like Netmeds are gaining an edge here with inhouse warehousing and freight facilities, thereby helping push down the logistics expenses.

The Indian healthcare market is further expected to reach $372 Bn by 2022, from according to a September 2018 IBEF report. Recently, the government also released final guidelines for epharma companies, in line with the draft Personal Data Protection Bill and DISHA Guidelines

An email sent to 1mg did not elicit any response till the time of publication.

Author

Meha Agarwal

Inc42 Staff

Meha has engineering and MBA degrees, but she has always been a writer at heart. It was the perfect combination of utilising her research and analytical skills and her enthusiasm for writing that sparked her interest in writing about the Indian startup ecosystem – the latest tech and gadgets and the startups that create them. She is always on the lookout for industry-specific stories in niche areas of interest such as ecommerce, fintech, greentech and more.

Responses
https://inc42.com/buzz/paypay-marks-official-foray-in-japan-with-paytms-qr-tech/
Loading Next…

Upcoming Events